
Moderna, Inc. (NASDAQ:MRNA) reported better-than-expected fourth-quarter earnings Thursday and announced a slight upward revision to its vaccine sales forecast for 2022. The company also announced a $3-billion stock buyback.
The stock rallied 15.1% in Thursday's trading session. Here's what two analysts had to say about the earnings results.